Talk:Sarcopenia

Cleaning up References section
Can someone please format the references section so it's not so much of a hodgepodge? —Preceding unsigned comment added by Thattherepaul (talk • contribs) 11:51, 16 August 2008 (UTC)
 * Done! Wingman4l7 (talk) 04:08, 9 July 2012 (UTC)

Veganism
Any references for the statement on improving BMD in veganism in senescence? Also, the body of literature seems heterogeneous on the incidence of sarcopenia and osteoporosis with meat intake... any solid evidence for that statement? —Preceding unsigned comment added by Vyapada (talk • contribs) 07:10, 22 April 2008 (UTC)

The difference between sarcopenia and cachexia
Is there a difference? I'm reading a report right now that talks about sarcopenic cachexia. I'd like to see an explanation that deals with the two terms. /Eribro 20:58, 1 November 2007 (UTC)


 * To answer your question – yes, many. Sarcopenia, as now commonly defined, is a loss of lean mass (muscle) associated with aging. Cachexia is a loss of total mass (muslce, fat, etc.), associated with disease (e.g., COPD, CHF, Cancer) or trauma (e.g., burn).  Sarcopenia seems to be mostly due to deconditioning and the loss of endogenous androgens as we age.  Cachexia is much more complex and heterogeneous.

Vitamin D deficiency
I added a ref and comment about this. Should a Notes section be established for that ref instead of adding as I did? Chaveso 18:44, 6 November 2007 (UTC)

Rewrite
I rewrote the article, because it was quite disorganized. I added a lot of sections, and tried to organize things better.

Gacggt (talk) 22:21, 10 January 2009 (UTC)

High carbohydrate as a risk factor
I've heard that there are some doctors, and now an organization of doctors, who believe that the major risk factor for Sarcopenic obesity, and possibly of Obesity, Sarcopenia in general, consequent Deconditioning, and the early onset of Type 2 Diabetes is too much carbohydrate in the diet. I believe this is too new a speculation to have any reliable sources, so I thought I'd just note it here. Also, note that the percentage body fat in various areas of the body (as opposed to the Body Mass Index) is easily measured by a GE two-energy-level x-ray scannter. Again, this is probably too new a device to have readily available reliable sources. These new insights and technologies may hold the promise of reducing the prevalence of sarcopenic and non-sarcopenic obesity in society. (In many cases, restrictive diets fail due to hunger--this may be less of a problem in high-protein, ketogenic diets. David Spector (talk) 23:04, 11 August 2010 (UTC)

Natural History section
I removed the following text from the Natural History section as it seemed to be a distracting level of detail that unbalanced the section. Rod57 (talk) 13:23, 2 November 2010 (UTC) "No substance-free, proven Olympic weight-lifting record has been set by any athlete of either sex or any weight class above the age of 31. ((However, in the non-Olympic sport of powerlifting, many world records in several weight divisions have been accomplished by athletes well into their forties, purportedly, "verified" by the International Powerlifting Federation to have been accomplished drug-free. However, that this certification carries any weight is doubtful considering that even in highly supervised events such as the Olympics, drug cheating invariably occurs (some of which is detected right away, much of it is not). Furthermore, casting doubt on any records set outside the traditional Olympic athletic system, drug cheating is rampant in professional sports that do not perform random drug testing (e.g. baseball).))"

Diet
Can we add more on the effect of diet on sarcopenia ? Increased requirement for protein as we age ? Rod57 (talk) 13:35, 2 November 2010 (UTC)

Evolutionary Considerations
I am a student at Case Western Reserve University interested in the evolutionary considerations of sarcopenia and muscle loss. The following is a sample of what I plan on adding to the article under the subtitle "Evolutionary Considerations." "Myostatin is a substance that the body produces in order to keep muscles from getting too large. Myostatin inhibitors will result in the success of muscle growth and may soon be used as a way to help people with muscle-wasting diseases. The two roles of myostatin are in embryo to limit formation of muscle fibers, and later in life to limit the growth of the muscle . There are a few hypotheses relating to why myostatin is genetically inherent." Furthermore, I will discuss the two opposing hypotheses on muscle-wasting as related to the proximate cause of myostatin in an ultimate, evolutionary, context. Tgdetto345 (talk) 18:18, 5 November 2013 (UTC)

Pictures, anyone..?
Hello, all. I'm teaching a course called Wiki-Med at the Sackler school of Medicine, Tel-Aviv University, Israel. My of my students is working on translating this article into Hebrew, but is missing pictures for better illustrating the phenomenon. Can anyone help us find / upload related pics? Please ignore any pics you might find now on commons. These were copied from google by and uploaded by the student by mistake and will be deleted shortly. Thanks much in advance, Shani. (talk) 23:17, 26 December 2013 (UTC)

Suggested edit
Hi all, I wanted to update the diagnostic criteria for sarcopenia under the diagnosis section with the following:

"...including the European Working Group on Sarcopenia in Older People (EWGSOP). Their consensus definition is:

1. A low muscle mass, (e.g. >2 standard deviations below that mean measured in young adults [aged 18–39 years in the 3rd NHANES population] of the same sex and ethnic background) and either, 2. Low gait speed (e.g. a walking speed below 0.8 m/s in the 4-m walking test). or 3. Low muscular strength (e.g. grip strength: <30kg in males, <20kg in females)

Severe sarcopenia requires the presence of all three conditions."

The citation is from the European Working Group on Sarcopenia in Older People (EWGSOP) and appears to be more recognised than the current definition. Please let me know if anyone has an opinion on this. — Preceding unsigned comment added by Danagg12 (talk • contribs) 16:26, 2 December 2016 (UTC)
 * There is already a citation to http://ageing.oxfordjournals.org/content/39/4/412 which is used to support the text in the Sarcopenia section. If you feel that repeating it in the Sarcopenia  section is helpful to the reader, the you should make the edit. It is sufficient to use   to create the reference for the text you add. --RexxS (talk) 15:13, 6 December 2016 (UTC)
 * There is already a citation to http://ageing.oxfordjournals.org/content/39/4/412 which is used to support the text in the Sarcopenia section. If you feel that repeating it in the Sarcopenia  section is helpful to the reader, the you should make the edit. It is sufficient to use   to create the reference for the text you add. --RexxS (talk) 15:13, 6 December 2016 (UTC)

New Reference, for ICD code
I added a reference to the new ICD code for Sarcopenia, but couldn't figure out how to incorporate it into the already-established reference list. Can someone help me? The reference is: http://aginginmotion.org/news/2388-2/ Thank you... Gacggt (talk) 15:57, 8 January 2017 (UTC)gacggt

When does it begin?
The lede says it begins "after the age of 50". When I first heard about, I was told it began at age 30. A very quick look at web search results indicates it begins sometime between age 30 and 40. SlowJog (talk) 15:19, 28 August 2019 (UTC)